Newsletters

CPCC acknowledges our sponsors by their logos below. Without their financial support, neither our newsletter nor our website could be produced and maintained.

A Leader in Active Immunotherapy
Dendritic Cell Immunotherapy

To view and print the Newsletter in "PDF" type format, you need to install Adobe Acrobat Reader. Download a free Reader by clicking

Current Edition
CPCC Newsletter April 2007
Volume 9, Issue 2, April 2007 ( 137 KB - Download)
There is substantial evidence of efficacy and safety of Provenge?? for the treatment of patients with asymptomatic, metastatic, androgen-independent prostate cancer Dendreon announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee recommended to the FDA that there is substantial evidence of the efficacy and safety of Provenge as a treatment for patients with asymptomatic, metastatic, androgen-independent Prostate Cancer (also known as hormone-refractory) prostate cancer.

Past Editions

CPCC Newsletter Volume 7, Issue 2, April 2005 ( 268 KB - Download)

CPCC Newsletter August 2005 Volume 7, Issue 4, August 2005 ( 452 KB - Download)

Making History in California Volume 8, Issue 8, February 2006 ( 1.8 MB - Download)

CPCC Newsletter April 2006 Volume 8, Issue 2, April 2006 ( 339 KB - Download)

CPCC NEWS Volume 8, Issue 3, June 2006 ( 592 KB - Download)

CPCC Newsletter Volume 8, Issue 4, August 2006 ( 456 KB - Download)

CPCC Newsletter Volume 8, Issue 5, October 2006 ( 361 KB - Download)

CPCC Newsletter February 2007 Volume 9, Issue 1, February 2007 ( 138 KB - Download)